ORIC Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jacob Chacko
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 240 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Apr 24, 2020
- CIK
- 0001796280
- Website
- oricpharma.com
- Similar Companies
- Business
- ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies to overcome resistance mechanisms in cancer. The company’s core product candidates include ORIC-114 (enozertinib), a brain-penetrant, orally bioavailable irreversible inhibitor selectively targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) exon 20 mutations; ORIC-944, a potent allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for metastatic castration-resistant prostate cancer (mCRPC); and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, targeting resistance to chemotherapy and immunotherapy. These products are designed to address key tumor dependencies and resistance in hormone-dependent cancers and precision oncology settings. Founded in 2018 and headquartered in South San Francisco, California, ORIC operates primarily in the United States but has extended its clinical trial activities internationally, including recent data presentations in Asia. The company’s business segments revolve around oncology drug discovery and development, targeting genetically defined cancer populations with precision therapeutics. In recent major developments, ORIC Pharmaceuticals secured significant funding with a $125 million private placement financing in 2024 to extend their operational runway into late 2026. The company entered into a strategic clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for first-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. Additionally, ORIC is progressing multiple Phase 1b clinical trials for its lead candidates ORIC-114, ORIC-944, and ORIC-533, with encouraging early safety and efficacy data reported for ORIC-944. The pipeline advancement is supported by a diversified strategy to tackle cancer resistance mechanisms through combinations with androgen receptor inhibitors and immuno-oncology approaches. ORIC Pharmaceuticals leverages its internal discovery capabilities alongside strategic partnerships to build a diverse pipeline of therapies for oncology, focusing on druggable subunits and precision medicine. Its clinical and operational focus emphasizes multiple cancer types, including lung and prostate cancers, positioning the company at the forefront of developing next-generation cancer treatments designed to overcome therapeutic resistance. This company profile reflects ORIC Pharmaceuticals, Inc.’s comprehensive product offerings, strategic collaborations, recent funding milestones, and ongoing clinical development roadmap as of late 2025.
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm